Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2019;34(5):1116-1124. Published online 2018 Jun 29 DOI: https://doi.org/10.3904/kjim.2018.011
Citations to this article as recorded by 
Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
Da Som Jeon, Cheol‐kyu Park, Seung Joon Kim, Chan Kwon Park, Yoon Soo Chang, Chi Young Jung, Sung Yong Lee, Shin‐Yup Lee, Jeong‐Seon Ryu, Jeong Eun Lee, Kye Young Lee, Tae Won Jang, Seung Hun Jang, Seong Hoon Yoon, Sang Hoon Lee, Chang‐min Choi, Hyeong Ry
Thoracic Cancer.2024; 15(6): 448. CrossRef
Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
Zihua Zou, Xuezhi Hao, Cuiying Zhang, Haojing Li, Guilan Dong, Yumei Peng, Kewei Ma, Ye Guo, Li Shan, Yan Zhang, Li Liang, Yangchun Gu, Puyuan Xing, Junling Li
Thoracic Cancer.2022; 13(1): 107. CrossRef
Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience
Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever
Clinical Cancer Investigation Journal.2022; 11(3): 25. CrossRef
Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer
Xianxiu Ji, Huikang Xie, Ren Zhu, Bin Chen, Sen Jiang, Jie Luo
Journal of International Medical Research.2021; 49(2): 030006052199364. CrossRef
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
Yen-Ting Lin, Yi-Nan Liu, Jin-Yuan Shih
Frontiers in Oncology.2019;[Epub] CrossRef